(Q30009098)

21 May 2017

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases (English)

1 reference

21 May 2017

Michela Silacci

1

1 reference

21 May 2017

Wibke Lembke

2

1 reference

21 May 2017

Richard Woods

3

1 reference

21 May 2017

Isabella Attinger-Toller

4

1 reference

21 May 2017

Nadja Baenziger-Tobler

5

1 reference

21 May 2017

Sarah Batey

6

1 reference

21 May 2017

Roger Santimaria

7

1 reference

21 May 2017

Ulrike von der Bey

8

1 reference

21 May 2017

Susann Koenig-Friedrich

9

1 reference

21 May 2017

Wenjuan Zha

10

1 reference

21 May 2017

Bernd Schlereth

11

1 reference

21 May 2017

Mathias Locher

12

1 reference

21 May 2017

Julian Bertschinger

13

1 reference

21 May 2017

Dragan Grabulovski

14

1 reference

21 May 2017

language of work or name

1 reference

22 September 2015

1 reference

21 May 2017

Monoclonal Antibodies

1 reference

21 May 2017

8

1 reference

21 May 2017

1

1 reference

21 May 2017

141-149

1 reference

A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action

21 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Bispecific antibodies for cancer immunotherapy: Current perspectives

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Structure of IL-17A in complex with a potent, fully human neutralizing antibody

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

22 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Anti-TNF treatment in rheumatoid arthritis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Selection of single domain binding proteins by covalent DNA display

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

Design and use of phage display libraries for the selection of antibodies and enzymes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4966518

To switch or to change class-the biologic dilemma in rheumatoid arthritis.

3 June 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1093266

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1093266

Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1093266

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F19420862.2015.1093266

Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis

21 January 2018

2 references

https://api.crossref.org/works/10.1080%2F19420862.2015.1093266

21 January 2018

12 December 2020

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys

1 reference

PubMed

12 December 2020

Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody

1 reference

PubMed

12 December 2020

Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma--a report of 2 cases

1 reference

PubMed

12 December 2020

10.1080/19420862.2015.1093266

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4795912

OpenCitations bibliographic resource ID

4795912

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

0 references

1 reference